Publications by authors named "Pallavi Bedi"
Purpose: Asthma is a common comorbidity in patients with bronchiectasis and has been shown to increase the risk of bronchiectasis exacerbations. This paper explores the impact of comorbid asthma on patients receiving intravenous antibiotic treatment for bronchiectasis exacerbations.
Methods: This was a post hoc analysis of the Meropenem randomised controlled trial of 90 patients that had intravenous antibiotic treatment for bronchiectasis exacerbations.
Introduction: Bronchiectasis is characterised by excessive neutrophilic inflammation. Lipid mediators such as prostaglandins and leukotrienes have crucial roles in the inflammatory response. Further characterisation of these lipids and understanding the interplay of anti-inflammatory and proinflammatory lipid mediators could lead to the development of novel anti-inflammatory therapies for bronchiectasis.
View Article and Find Full Text PDFArticle Synopsis
- A study aimed to explore if the duration of intravenous antibiotics for bronchiectasis exacerbations could be shortened based on bacterial load, comparing a 14-day treatment group with a bacterial load-guided group (BLGG).
- Of the participants, 88% in the BLGG stopped antibiotics by day 8, whereas some in the 14-day group might have done the same, but those on 14 days experienced more exacerbations overall.
- Although there was a slight trend for improved clinical outcomes by day 21 with the 14-day regimen, the BLGG showed a significantly longer time to the next exacerbation, suggesting that shorter treatment might be adequate for most cases.
The full British Thoracic Society Guideline for Bronchiectasis in Adults is published in . The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.
View Article and Find Full Text PDFBackground: A validated clinical end point is needed to assess response to therapies in bronchiectasis.
Objectives: The goal of this study was to assess the reliability, validity, and responsiveness of the incremental shuttle walk test (ISWT) as a clinical end point in bronchiectasis.
Methods: In clinically stable patients (n = 30), the ISWT was performed twice, 6 months apart.
In bronchiectasis, exacerbations are believed to be triggered by infectious agents, but often no pathogen can be identified. We hypothesised that acute air pollution exposure may be associated with bronchiectasis exacerbations.We combined a case-crossover design with distributed lag models in an observational record linkage study.
View Article and Find Full Text PDFRationale: Excessive neutrophilic airway inflammation is the central feature of bronchiectasis, but little is known about neutrophils in bronchiectasis.
Objectives: To assess blood neutrophil phenotype in patients with bronchiectasis while stable and during exacerbations.
Methods: In the clinically stable arm of this study, there were eight healthy volunteers, eight patients with mild bronchiectasis, and eight patients with severe bronchiectasis.
Objectives: The goal of this study was to develop a simplified radiological score that could assess clinical disease severity in bronchiectasis.
Methods: The Bronchiectasis Radiologically Indexed CT Score (BRICS) was devised based on a multivariable analysis of the Bhalla score and its ability in predicting clinical parameters of severity. The score was then externally validated in six centers in 302 patients.
Background: There are no randomized controlled trials of statin therapy in patients with severe bronchiectasis who are chronically infected with Pseudomonas aeruginosa.
Methods: Thirty-two patients chronically infected with P aeruginosa were recruited in this double-blind cross-over randomized controlled trial. Sixteen patients were recruited in each arm, were given atorvastatin 80 mg or placebo for 3 months followed by a washout period for 6 weeks, and then crossed over and administered the alternative therapy for 3 months.
Background: Interest in the association of vascular disease with COPD and pneumonia has increased, but there is a lack of research in this area with patients with bronchiectasis.
Methods: A retrospective study of 400 patients attending a specialist bronchiectasis clinic in NHS Lothian (Edinburgh, UK) between May 2013 and September 2014 was conducted. The study assessed the prevalence of vascular disease (ischemic heart disease, cerebrovascular disease, peripheral vascular disease, and atrial fibrillation).
Background: We introduced domiciliary intravenous (IV) antibiotic therapy in patients with bronchiectasis to promote patient-centred domiciliary treatment instead of hospital inpatient treatment.
Aim: To assess the efficacy and safety of domiciliary IV antibiotic therapy in patients with non-cystic fibrosis bronchiectasis.
Methods: In this prospective study conducted over 5 years, we assessed patients' eligibility for receiving domiciliary treatment.